There are currently 150 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and New York.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Recruiting
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +74 locations
Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Recruiting
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: KisMET-01 Clinical Site, Santa Monica, California +19 locations
Conditions: NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Recruiting
Background: - Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gather tissue samples from people with lung and thymic cancers to understand the disease better. This may lead to new ways to diagnose and treat it. Objective: - To collect tissue samples for use in the study of lung cancers. Eligibility: - Adults over age 18 with non-small cell lung cancer, small cell lung cancer, extra pulmonary small cel... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, Thymic Epithelial Tumors
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Recruiting
Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. One approach to treating these cancers is to take disease-fighting white blood cells from a person, change those cells so they will target the specific proteins (called antigens) from the cancer cells, and return them to that person s blood. The use of the white blood cells in this manner is one form of gene therapy. A vaccine may help these modi... Read More
Gender:
All
Ages:
Between 18 years and 72 years
Trial Updated:
03/26/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Recruiting
Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments. Objective: To better understand the biology of malignancies and why certain cancers respond differently to treatment. Eligibility: Adults at least 18 years old with cancer or a pre-cancerous condition. De... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
03/26/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease, Non-Small Cell Lung Cancer
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Recruiting
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: City of Hope, Duarte, California +5 locations
Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D) will be explored. Each treatment arm rece... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: University of California, Los Angeles /ID# 243841, Los Angeles, California +75 locations
Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
Recruiting
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times p... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
03/25/2024
Locations: Highlands Oncology Group, PA, Fayetteville, Arkansas +28 locations
Conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Recruiting
Background: Surgery is the primary treatment for non-small cell lung cancer (NSCLC) that is diagnosed in its earlier stages. But the tumors often return. Radiation and chemotherapy can improve survival in some people who have had surgery for NSCLC, but these treatments also cause serious side effects. A new approach, called immunotherapy, may be a better way to stop NSCLC tumors from coming back. Objective: To test a new treatment (H1299 lung cancer cell vaccine combined with the drug N-803)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Recruiting
This study will test the safety of Quad Shot radiation therapy using 2 different treatment schedules to find out what effects, if any, this treatment has on people with advanced NSCLC who are receiving systemic therapy for their cancer. The Quad Shot treatment schedule reduces the number of days needed to deliver the radiation treatments, which may be less disruptive to systemic therapy schedules.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Non-Small Cell Lung Cancer
A Study of CDX-585 in Patients With Advanced Malignancies
Recruiting
This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: George Washington University Cancer Center, Washington, District of Columbia +3 locations
Conditions: Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
Recruiting
The standard treatment for patients with Non-Small Cell Lung Cancer (NSCLC) and clinically negative lymph nodes remains surgery per current guidelines. Five year survival for patients with stage I non-small cell lung cancer is generally greater than 50% after surgery. Many of these patients have heart and lung issues or other diseases which keep them from undergoing curative surgery. Studies have shown that majority of these patients die from their cancer and not from their other diseases. This... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: SUNY Upstate Medical University, Syracuse, New York
Conditions: Non-small Cell Lung Cancer